- Home
- TBI vs RAPT Comparison
TBI vs RAPT Comparison
Compare TBI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- RAPT
- Stock Information
- Founded
- TBI 1985
- RAPT 2015
- Country
- TBI United States
- RAPT United States
- Employees
- TBI N/A
- RAPT N/A
- Industry
- TBI Professional Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- RAPT Health Care
- Exchange
- TBI Nasdaq
- RAPT Nasdaq
- Market Cap
- TBI 127.9M
- RAPT 117.5M
- IPO Year
- TBI 1996
- RAPT 2019
- Fundamental
- Price
- TBI $4.41
- RAPT $0.75
- Analyst Decision
- TBI Buy
- RAPT Hold
- Analyst Count
- TBI 2
- RAPT 7
- Target Price
- TBI $11.50
- RAPT $5.00
- AVG Volume (30 Days)
- TBI 267.2K
- RAPT 841.0K
- Earning Date
- TBI 05-05-2025
- RAPT 05-08-2025
- Dividend Yield
- TBI N/A
- RAPT N/A
- EPS Growth
- TBI N/A
- RAPT N/A
- EPS
- TBI N/A
- RAPT N/A
- Revenue
- TBI $1,534,794,000.00
- RAPT N/A
- Revenue This Year
- TBI N/A
- RAPT N/A
- Revenue Next Year
- TBI $9.22
- RAPT N/A
- P/E Ratio
- TBI N/A
- RAPT N/A
- Revenue Growth
- TBI N/A
- RAPT N/A
- 52 Week Low
- TBI $3.45
- RAPT $0.75
- 52 Week High
- TBI $12.29
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- TBI 46.72
- RAPT 33.73
- Support Level
- TBI $3.45
- RAPT $0.75
- Resistance Level
- TBI $4.62
- RAPT $0.85
- Average True Range (ATR)
- TBI 0.30
- RAPT 0.08
- MACD
- TBI 0.05
- RAPT -0.00
- Stochastic Oscillator
- TBI 80.00
- RAPT 0.97
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.